Cargando…

Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease

Detalles Bibliográficos
Autores principales:	Faridi, Kamil F., Desai, Nihar R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036885/ https://www.ncbi.nlm.nih.gov/pubmed/36969953 http://dx.doi.org/10.1016/j.ajpc.2023.100491

Ejemplares similares

Nonadherence to lipid‐lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
por: Desai, Nihar R., et al.
Publicado: (2022)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline
por: Journath, Gunilla, et al.
Publicado: (2017)

Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases
por: Choi, Su-Yeon, et al.
Publicado: (2020)

Metabolomics: moving towards personalized medicine
por: Baraldi, Eugenio, et al.
Publicado: (2009)

MALDI MSI for a fresh view on atherosclerotic plaque lipids
por: Worthmann, Anna, et al.
Publicado: (2021)

Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
por: Imyanitov, Evgeny N
Publicado: (2009)

Moving towards the goals of FP2020 — classifying contraceptives()
por: Festin, Mario Philip R., et al.
Publicado: (2016)

All the right moves: the need for the timely use of hyperbaric oxygen therapy for treating TBI/CTE/PTSD
por: Stoller, Kenneth P.
Publicado: (2015)

Lipid-Lowering Drug Effects Beyond the Cardiovascular System: Relevance for Neuropsychiatric Disorders
por: Lohoff, Falk W
Publicado: (2018)

Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease
por: Shehadeh, Naim, et al.
Publicado: (2018)

Moving the Needle on Atherosclerotic Cardiovascular Disease and Heart Failure with Influenza Vaccination
por: Behrouzi, Bahar, et al.
Publicado: (2021)

Moving toward genome-editing therapies for cardiovascular diseases
por: Musunuru, Kiran
Publicado: (2022)

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
por: Cannon, Christopher P., et al.
Publicado: (2021)

Exploring Contemporary Data on Lipid-Lowering Therapy Prescribing in Patients Following Discharge for Atherosclerotic Cardiovascular Disease in the South of Italy
por: Citarella, Anna, et al.
Publicado: (2022)

Why Current Therapy Does Not Cure Asthma. Is It Time to Move Towards a One Health Approach?
por: Rolla, Giovanni
Publicado: (2023)

Moving towards a more realistic concept of what constitutes Alzheimer's disease
por: Hölscher, Christian
Publicado: (2018)

2022: the year in cardiovascular disease – the year of upfront lipid lowering combination therapy
por: Banach, Maciej, et al.
Publicado: (2022)

Moving Toward Impact: An Introduction to Implementation Science for Gastroenterologists and Hepatologists
por: Rogal, Shari S., et al.
Publicado: (2020)

Commentary: Moving towards “mark-less” toric IOL alignment
por: Titiyal, Jeewan S, et al.
Publicado: (2020)

Moving from the stratification of primary and secondary prevention of cardiovascular risk in diabetes towards a continuum of risk: need for a new paradigm
por: Garcia-Moll, Xavier, et al.
Publicado: (2021)

Migraine Outcome Should Not Be Used to Determine Diagnosis, Severity, and Therapy: Moving Towards a Multiparametric Definition of Chronicity
por: Raggi, Alberto, et al.
Publicado: (2022)

Could Lowering Phytosterol Absorption as Part of Lipid-Lowering Therapy Have a Beneficial Effect on Residual Risk?
por: Anagnostis, Panagiotis, et al.
Publicado: (2023)

Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses
por: Shaya, Fadia Tohme, et al.
Publicado: (2019)

Case report: Coronary atherosclerosis in a patient with long-standing very low LDL-C without lipid-lowering therapy
por: Mottola, Giorgio, et al.
Publicado: (2023)

siRNA targeting ANGPTL3 stands in the spotlight for lipid-lowering therapy
por: Hu, Bo, et al.
Publicado: (2023)

SNAP – A Large Step in the Move towards Personalised Dosing of Acetylcysteine
por: Chiew, Angela L., et al.
Publicado: (2019)

The Data Governance Act and the EU's move towards facilitating data sharing
por: Shabani, Mahsa
Publicado: (2021)

Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States
por: Valero-Elizondo, Javier, et al.
Publicado: (2021)

Low-density lipoprotein cholesterol lowering therapy for the secondary prevention of atherosclerotic cardiovascular disease
por: Patel, Parth N., et al.
Publicado: (2020)

Moving toward a prevention strategy for osteoporosis by giving a voice to a silent disease
por: Jepsen, Karl J., et al.
Publicado: (2016)

Adipose-derived stem cells for cartilage regeneration - moving towards clinical applicability
por: Labusca, Luminita, et al.
Publicado: (2013)

Moving towards individualised and interdisciplinary approaches to treat persistent post-concussion symptoms
por: Jaganathan, Kannan Singaravelu, et al.
Publicado: (2020)

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
por: Nelson, Adam J., et al.
Publicado: (2022)

Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions
por: Desai, Aakash, et al.
Publicado: (2020)

Identification and treatment of those most at risk for premature atherosclerotic cardiovascular disease: We just cannot seem to get it right
por: Toth, Peter P.
Publicado: (2020)

Androgen therapy and atherosclerotic cardiovascular disease
por: McGrath, K-CY, et al.
Publicado: (2008)

Measures of Financial Hardship From Health Care Expenses Among Families With a Member With Atherosclerotic Cardiovascular Disease in the US
por: Wang, Stephen Y., et al.
Publicado: (2022)

Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan
por: Sagan, Selena M., et al.
Publicado: (2016)

COVID-19 zugzwang: Potential public health moves towards population (herd) immunity
por: Bhopal, Raj S.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vmsanjr085tn98p50pknom6r32